Fabtech Technologies will host one-on-one interactions with investors and analysts in Mumbai on September 24, 2026. The sessions are scheduled at 10:00 am and 11:30 am IST, facilitated by investor relations firm Kaptify Consulting.

The management will engage with a Family Office Fund and a Domestic Institutional Investor. These meetings are conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ensuring compliance with disclosure norms regarding corporate communications.

Meeting Schedule

The company has outlined the specific timing and participant details for the upcoming interactions.

Disclosure Compliance

Fabtech Technologies stated that no unpublished price sensitive information will be discussed during these sessions. All conversations with investors and analysts will be based strictly on publicly available information. The company noted that the meetings may be cancelled, rescheduled, or postponed due to unavoidable exigencies.

The intimation was filed with the National Stock Exchange of India and BSE Limited by Hemant Mohan Anavkar, Executive Director, on September 23, 2026.

What Happened

Fabtech Technologies has been awarded a confirmed work order valued at Rs 21.0 crore by a customer in a CIS country. The contract covers a turnkey design-and-build project for critical internal infrastructure of an advanced medical-device manufacturing facility. Scope includes integrated engineering, cleanroom systems, HVAC, building management systems, electrical systems, process and clean utilities, laboratory furniture, fire and life-safety systems, installation, testing, and commissioning. The execution timeline is set at 12 months.

Order in Financial Context

The Rs 21.0 crore order represents approximately 19% of the company's average quarterly revenue of Rs 110.30 crore. When viewed against the broader pipeline, the Total Disclosed Order Book (sum of the 5 orders disclosed across the last 3 fiscal quarters shown in the table below) stands at Rs 149.52 crore. This results in a book-to-bill ratio of roughly 0.34x when compared to TTM revenue, indicating that the company is not currently building a large deferred revenue buffer. The existing backlog covers only 1.36 quarters of average quarterly revenue, suggesting that consistent order inflow is necessary to maintain current revenue run-rates.

Company Order Track Record

Order inflow velocity appears to have decelerated in the most recent quarter compared to the heavy concentration seen in Q1FY27. The current order value of Rs 21.0 crore is smaller than the typical per-order size visible in the recent history, where multiple orders in the range of Rs 31.23 crore were booked. The company has received orders from multiple entity types, including domestic clients like Aroma King and international clients in Botswana and CIS countries.

Execution and Revenue Quality

Revenue execution has shown volatility over the last three quarters. Q4FY26 was a strong quarter with revenue of Rs 168.40 crore and an operating profit margin (OPM) of 14.01%. However, Q1FY27 saw a significant contraction, with revenue dropping to Rs 78.20 crore and OPM compressing to 5.63%. Notably, Q3FY26 recorded a net loss of Rs 5.70 crore and negative OPM of -18.48%, signaling prior execution stress that has since improved but remains unstable.

Revenue Growth - Order Wins Translating to Revenue

As Fabtech technologies has sustained order wins, with a notable spike in inflows during Q1FY27, its annual revenue has grown from Rs 335.90 crore in FY25 to Rs 410.77 crore in FY26, representing a YoY growth of +22.3% based on the latest annual data. Despite this top-line growth, net profit declined by -21.5% in FY26, highlighting margin pressure during the transition phase.

Working Capital and Execution Capacity

The balance sheet provides strong support for execution capacity. With a current ratio of 2.50x, the company holds sufficient liquidity to manage working capital cycles for ongoing projects. The Total Liabilities/Equity ratio stands at a conservative 0.56x, indicating low financial leverage. However, operating cashflow turned negative at -Rs 36.10 crore in FY25, suggesting that while profits are being booked, cash conversion efficiency requires monitoring as receivables or working capital may be stretched.

What to Watch

• Execution rate: Monitor whether the 12-month timeline for the CIS country order translates into stable quarterly revenue, given the recent dip in Q1FY27.
• OPM trajectory: The compression from 14.01% in Q4FY26 to 5.63% in Q1FY27 warrants scrutiny; it is important to observe if the new order maintains historical margin quality.
• Cash conversion: Negative operating cashflow in FY25 indicates potential working capital strain; positive reversal in upcoming quarters will be key.
• Client concentration: The recent order book includes international vaccine facilities and now a CIS country medical facility; diversification into sectors like flavour manufacturing may reduce sector-specific risks.

Key Observations

• Margin stress: Net loss of Rs 5.70 crore in Q3FY26; execution stress visible in quarterly data.
• Valuation check (as of 17 Sep 2026): P/E of 13.3x against ROCE of 31.09%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios.
• Cash conversion: Operating cashflow of -Rs 36.10 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched.